$WST
WEST PHARMACEUTICAL SERVICES INC Stock $wst

$wst Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000010577023000068 Filed on October 26, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$732.0M	$747.4M
YoY Change	3.29%	8.81%
Cost Of Revenue	$453.8M	$459.1M
YoY Change	1.61%	9.6%
Gross Profit	$278.2M	$288.3M
YoY Change	6.14%	7.57%
Gross Profit Margin	38.01%	38.57%
Selling, General & Admin	$90.00M	$89.00M
YoY Change	5.02%	34.24%
% of Gross Profit	32.35%	30.87%
Research & Development	$18.40M	$16.40M
YoY Change	15.72%	20.59%
% of Gross Profit	6.61%	5.69%
Depreciation & Amortization	$35.90M	$35.70M
YoY Change	15.43%	19.8%
% of Gross Profit	12.9%	12.38%
Operating Expenses	$117.3M	$105.4M
YoY Change	9.83%	31.91%
Operating Profit	$160.9M	$177.3M
YoY Change	3.61%	-4.78%
Interest Expense	$8.200M	$2.900M
YoY Change	272.73%	31.82%
% of Operating Profit	5.1%	1.64%
Other Income/Expense, Net	-$900.0K	$9.700M
YoY Change	12.5%	-119.4%
Pretax Income	$168.2M	$187.0M
YoY Change	30.69%	37.3%
Income Tax	$34.50M	$29.40M
% Of Pretax Income	20.51%	15.72%
Net Earnings	$137.0M	$161.3M
YoY Change	33.01%	33.75%
Net Earnings / Revenue	18.72%	21.58%
Basic Earnings Per Share		$2.17
Diluted Earnings Per Share	$1.83	$2.14
COMMON SHARES
Basic Shares Outstanding	73.99M shares	73.86M shares
Diluted Shares Outstanding		75.30M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$853.9M	$898.6M
YoY Change	-4.52%	23.26%
Cash & Equivalents	$853.9M	$898.6M
Short-Term Investments
Other Short-Term Assets	$135.8M	$122.8M
YoY Change	31.84%	15.63%
Inventory	$434.7M	$431.8M
Prepaid Expenses
Receivables	$512.0M	$519.1M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.936B	$1.972B
YoY Change	0.88%	13.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.413B	$1.312B
YoY Change	22.02%	22.69%
Goodwill	$108.5M	$106.8M
YoY Change	1.12%	2.69%
Intangibles	$15.10M	$15.70M
YoY Change	-17.93%	-13.26%
Long-Term Investments	$203.2M	$189.7M
YoY Change	3.15%	7.05%
Other Assets	$21.30M	$38.80M
YoY Change	-44.09%	-26.38%
Total Long-Term Assets	$1.893B	$1.782B
YoY Change	11.54%	12.58%
TOTAL ASSETS
Total Short-Term Assets	$1.936B	$1.972B
Total Long-Term Assets	$1.893B	$1.782B
Total Assets	$3.830B	$3.755B
YoY Change	5.88%	13.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$242.4M	$219.8M
YoY Change	12.53%	16.36%
Accrued Expenses	$123.6M	$107.0M
YoY Change	30.24%	30.01%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$134.0M	$55.20M
YoY Change	5990.91%	2409.09%
Total Short-Term Liabilities	$671.8M	$533.5M
YoY Change	29.44%	16.82%
LONG-TERM LIABILITIES
Long-Term Debt	$72.80M	$152.1M
YoY Change	-64.78%	-26.59%
Other Long-Term Liabilities	$58.50M	$55.10M
YoY Change	13.37%	62.54%
Total Long-Term Liabilities	$131.3M	$207.2M
YoY Change	-49.17%	-14.06%
TOTAL LIABILITIES
Total Short-Term Liabilities	$671.8M	$533.5M
Total Long-Term Liabilities	$131.3M	$207.2M
Total Liabilities	$948.5M	$886.5M
YoY Change	1.78%	4.79%
SHAREHOLDERS EQUITY
Retained Earnings	$3.523B	$3.416B
YoY Change	17.93%	17.26%
Common Stock	$18.80M	$18.80M
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.881B	$2.868B
YoY Change
Total Liabilities & Shareholders Equity	$3.830B	$3.755B
YoY Change	5.88%	13.2%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	$137.0M	$161.3M
YoY Change	33.01%	33.75%
Depreciation, Depletion And Amortization	$35.90M	$35.70M
YoY Change	15.43%	19.8%
Cash From Operating Activities	$239.1M	$230.1M
YoY Change	3.6%	36.23%
INVESTING ACTIVITIES
Capital Expenditures	$108.7M	$95.80M
YoY Change	14.54%	-265.74%
Acquisitions
YoY Change
Other Investing Activities	-$100.0K	$100.0K
YoY Change	-200.0%	-107.69%
Cash From Investing Activities	-$108.8M	-$95.70M
YoY Change	14.77%	61.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-189.5M	-22.30M
YoY Change	1894.74%	-70.35%
NET CHANGE
Cash From Operating Activities	239.1M	230.1M
Cash From Investing Activities	-108.8M	-95.70M
Cash From Financing Activities	-189.5M	-22.30M
Net Change In Cash	-59.20M	112.1M
YoY Change	-146.8%	223.99%
FREE CASH FLOW
Cash From Operating Activities	$239.1M	$230.1M
Capital Expenditures	$108.7M	$95.80M
Free Cash Flow	$130.4M	$134.3M
YoY Change	-4.05%	-40.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0.0	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0.0	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0.0	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0.0	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-100000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-100000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-200000	usd
	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Curtailments DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments	0	usd
	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Curtailments DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments	-50800000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	13500000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	17900000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	47300000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	130700000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	537400000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	493200000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	253300000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	189700000	usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	6600000	usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	3700000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-259900000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-193400000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-3100000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-49300000	usd
	us-gaap	Net Income Loss NetIncomeLoss	482900000	usd
	wst	Contract With Customer Asset Increase Decrease ContractWithCustomerAssetIncreaseDecrease	3600000	usd
	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	18200000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	120600000	usd
	us-gaap	Net Income Loss NetIncomeLoss	456400000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74400000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74400000	shares
CY2022Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1300000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1100000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1500000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75700000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75500000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75900000	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	200000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	100000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	100000	shares
CY2023Q1	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	1000000000	shares
CY2023Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	27800000	usd
CY2023Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	360.25
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	753399	shares
	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	346.86
CY2022Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	27200000	usd
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	563334	shares
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	202900000	usd
	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	360.03
CY2023Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	180200000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	170700000	usd
CY2023Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	93800000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	79000000.0	usd
CY2023Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	157800000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	165100000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	431800000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	414800000	usd
CY2023Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	4500000	usd
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	3700000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	14400000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	10000000.0	usd
CY2023Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3100000	usd
CY2022Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	14000000.0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6600000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	29500000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y3M18D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0346
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0325
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	4800000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	19000000.0	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	19100000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	17100000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	16000000.0	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	14100000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	13400000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	9800000	usd
CY2023Q3	wst	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	50600000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	50800000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	115500000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	126700000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	17700000	usd
	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	-4400000	usd
CY2022Q3	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	49600000	usd
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1300000	usd
CY2013Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	20000000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74400000	shares
CY2021Q4	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	650000	shares
CY2022Q3	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	86667	shares
	us-gaap	Operating Lease Cost OperatingLeaseCost	15000000.0	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	10400000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	18100000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	9400000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	16000000.0	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	99500000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	109000000.0	usd
CY2023Q3	us-gaap	Equity Method Investments EquityMethodInvestments	189700000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	197000000	usd
CY2023Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	5700000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	7900000	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	207500000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	209200000	usd
CY2023Q3	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	200000	usd
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	300000	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	207300000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	208900000	usd
CY2023Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	55200000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2200000	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	152100000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	206700000	usd
CY2023Q3	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	2000000.0	usd
CY2022Q3	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	-2200000	usd
	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	1700000	usd
CY2023Q3	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	9100000	usd
CY2023Q3	us-gaap	Other Assets Fair Value Disclosure OtherAssetsFairValueDisclosure	1400000	usd
CY2023Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	35000000.0	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	4000000.0	usd
CY2023Q3	us-gaap	Other Deferred Compensation Arrangements Liability Classified Noncurrent OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent	9300000	usd
CY2023Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	25400000	usd
CY2022Q4	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	12500000	usd
CY2022Q4	us-gaap	Other Assets Fair Value Disclosure OtherAssetsFairValueDisclosure	1200000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	32100000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	4700000	usd
CY2022Q4	us-gaap	Other Deferred Compensation Arrangements Liability Classified Noncurrent OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent	12700000	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	18800000	usd
CY2023Q3	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	147200000	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	152100000	usd
CY2022Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	201800000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	206700000	usd
	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	-45900000	usd
	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-5900000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-40000000.0	usd
	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	-163300000	usd
	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-14400000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-148900000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2684900000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	140000000.0	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11000000.0	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	60100000	usd
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.19
CY2023Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	14200000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	14600000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	2776200000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	155100000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	18000000.0	usd
CY2023Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	173400000	usd
CY2023Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.19
CY2023Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	14100000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-15100000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2746700000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	161300000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	27500000	usd
CY2023Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	27800000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-39500000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	2868200000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2335400000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	173800000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	100000	usd
CY2022Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	147100000	usd
CY2022Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.18
CY2022Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	13200000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-22800000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	2326200000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	188500000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	15100000	usd
CY2022Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	28600000	usd
CY2022Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.18
CY2022Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	13300000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-63500000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	15600000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-62600000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	2470800000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1438454	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	105640	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	306.92
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	108.88
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.041
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.298
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.003
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5900000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21900000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6000000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17000000	usd
CY2023Q3	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	200000	usd
CY2022Q3	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	300000	usd
CY2023Q3	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	700000	usd
CY2022Q3	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	600000	usd
CY2023Q3	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	400000	usd
CY2022Q3	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	800000	usd
CY2023Q3	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	300000	usd
CY2022Q3	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	100000	usd
CY2023Q3	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1 DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1	0	usd
CY2022Q3	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1 DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1	-49600000	usd
CY2023Q3	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	200000	usd
CY2022Q3	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	49600000	usd
CY2023Q3	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	200000	usd
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	800000	usd
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	1000000.0	usd
	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	2000000.0	usd
	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	3800000	usd
	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	1000000.0	usd
	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	5400000	usd
	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	1100000	usd
	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	100000	usd
	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1 DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1	0	usd
	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1 DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1	-50800000	usd
	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	700000	usd
	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	50100000	usd
	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	700000	usd
	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	50100000	usd
CY2023Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2022Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-11600000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2023Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3500000	usd
CY2022Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1400000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	6900000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1600000	usd
CY2023Q3	us-gaap	Restructuring And Related Cost Incurred Cost RestructuringAndRelatedCostIncurredCost	0	usd
CY2022Q3	us-gaap	Restructuring And Related Cost Incurred Cost RestructuringAndRelatedCostIncurredCost	0	usd
	us-gaap	Restructuring And Related Cost Incurred Cost RestructuringAndRelatedCostIncurredCost	-800000	usd
	us-gaap	Restructuring And Related Cost Incurred Cost RestructuringAndRelatedCostIncurredCost	-1600000	usd
CY2023Q3	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	500000	usd
CY2022Q3	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-1500000	usd
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-500000	usd
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	1600000	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	700000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1500000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1500000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2600000	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1800000	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2200000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3000000.0	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	4600000	usd
CY2023Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-100000	usd
CY2022Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	300000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	200000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	400000	usd
CY2023Q3	wst	Other Income Expense OtherIncomeExpense	-5600000	usd
CY2022Q3	wst	Other Income Expense OtherIncomeExpense	-1900000	usd
	wst	Other Income Expense OtherIncomeExpense	-22500000	usd
	wst	Other Income Expense OtherIncomeExpense	4000000.0	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-11600000	usd
	wst	Number Of Manufacturing Facilities Sold NumberOfManufacturingFacilitiesSold	1	facility
CY2022Q4	wst	Restructuring And Related Activities Period Of Implementation RestructuringAndRelatedActivitiesPeriodOfImplementation	P24M
CY2023Q3	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	500000	usd
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-500000	usd
CY2022Q3	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-1500000	usd
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	1600000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29400000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20400000	usd
CY2023Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.157
CY2022Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.150
CY2022Q3	wst	Effective Income Tax Rate Reconciliation Termination Of Pension Plan Amount EffectiveIncomeTaxRateReconciliationTerminationOfPensionPlanAmount	-20000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	87800000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	85800000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.166
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.156
	wst	Effective Income Tax Rate Reconciliation Termination Of Pension Plan Amount EffectiveIncomeTaxRateReconciliationTerminationOfPensionPlanAmount	-20300000	usd
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5900000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	747400000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	686900000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2217800000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2178200000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	177300000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	186200000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	515100000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	604300000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9700000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-50000000.0	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14700000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-53100000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	187000000.0	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	136200000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	529800000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	551200000	usd
	wst	Number Of Manufacturing Facilities Sold NumberOfManufacturingFacilitiesSold	1	facility
CY2023Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0000105770-23-000068-index-headers.html	Edgar Link	pending
0000105770-23-000068-index.html	Edgar Link	pending
0000105770-23-000068.txt	Edgar Link	pending
0000105770-23-000068-xbrl.zip	Edgar Link	pending
amendedrestatedbylawsoct20.htm	Edgar Link	pending
ex311q32023.htm	Edgar Link	pending
ex312q32023.htm	Edgar Link	pending
ex321q32023.htm	Edgar Link	pending
ex322q32023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
wst-20230930.htm	Edgar Link	pending
wst-20230930.xsd	Edgar Link	pending
wst-20230930_def.xml	Edgar Link	unprocessable
wst-20230930_cal.xml	Edgar Link	unprocessable
wst-20230930_lab.xml	Edgar Link	unprocessable
wst-20230930_pre.xml	Edgar Link	unprocessable
wst-20230930_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$WST
WEST PHARMACEUTICAL SERVICES INC Stock $wst

2023 Q4 Form 10-Q Financial Statement

#000010577023000068 Filed on October 26, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WST WEST PHARMACEUTICAL SERVICES INC Stock $wst

2023 Q4 Form 10-Q Financial Statement

#000010577023000068 Filed on October 26, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WST
WEST PHARMACEUTICAL SERVICES INC Stock $wst